Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,901
  • Shares Outstanding, K 10,086
  • Annual Sales, $ 120 K
  • Annual Income, $ -8,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 2.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.49

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +15.69%
on 02/05/26
1.4100 -16.31%
on 01/28/26
-0.1600 (-11.94%)
since 01/27/26
3-Month
1.0200 +15.69%
on 02/05/26
1.6950 -30.38%
on 12/12/25
-0.2900 (-19.73%)
since 11/26/25
52-Week
1.0200 +15.69%
on 02/05/26
6.2299 -81.06%
on 08/18/25
-1.0700 (-47.56%)
since 02/27/25

Most Recent Stories

More News
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease

Soligenix (NASDAQ: SNGX) announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive recommendation for orphan drug designation of dusquetide, the active ingredient...

SNGX : 1.1800 (+2.61%)
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

PRINCETON, N.J. , Feb. 26, 2026 /PRNewswire/ -- Soligenix, Inc.  (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.1800 (+2.61%)
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Soligenix (NASDAQ: SNGX) announced that Christopher J. Schaber, Ph.D., president and chief executive officer, will deliver a corporate presentation at the BIO Investment & Growth Summit at 3 p.m. on March...

SNGX : 1.1800 (+2.61%)
Soligenix to Present at BIO Investment & Growth Summit

PRINCETON, N.J. , Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.1800 (+2.61%)
Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated 2026 milestones across its late-stage rare disease pipeline, including top-line...

SNGX : 1.1800 (+2.61%)
Soligenix Details Recent Progress and Upcoming Milestones

PRINCETON, N.J. , Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...

SNGX : 1.1800 (+2.61%)
Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality...

SNGX : 1.1800 (+2.61%)
BMWYY : 29.2000 (+4.58%)
Soligenix’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach

Soligenix (NASDAQ: SNGX) was featured in a recent article that discussed the company’s release of positive top-line results from its phase 2 clinical trial evaluating SGX945 for the treatment of aphthous...

SNGX : 1.1800 (+2.61%)
Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification...

SNGX : 1.1800 (+2.61%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more...

SNGX : 1.1800 (+2.61%)
BMWYY : 29.2000 (+4.58%)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 1.2550
2nd Resistance Point 1.2200
1st Resistance Point 1.2000
Last Price 1.1800
1st Support Level 1.1450
2nd Support Level 1.1100
3rd Support Level 1.0900

See More

52-Week High 6.2299
Fibonacci 61.8% 4.2397
Fibonacci 50% 3.6249
Fibonacci 38.2% 3.0102
Last Price 1.1800
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar